Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Eur J Cancer ; 154: 246-252, 2021 09.
Article in English | MEDLINE | ID: covidwho-1333382


BACKGROUND: Specific data regarding coronavirus disease 2019 (COVID-19) in patients with neuroendocrine neoplasms (NENs) are lacking. The aim of this study is to describe the characteristics of patients with NENs who tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive. MATERIAL AND METHODS: This is a worldwide study collecting cases of patients with NENs along with a positive nasopharyngeal swab reverse transcriptase-polymerase chain reaction (RT-PCR) test for SARS-CoV-2 between June 1, 2020, and March 31, 2021. Centres treating patients with NENs were directly contacted by the principal investigator. Patients with NENs of any primary site, grade and stage were included, excluding small-cell lung carcinoma and mixed adenoneuroendocrine carcinoma. RESULTS: Among 81 centres directly contacted, 88.8% responded and 48.6% of them declined due to lack of cases or interest. On March 31st, 2021, eight recruiting centres enrolled 89 patients. The median age was 64 years at the time of COVID-19 diagnosis. Most patients had metastatic, non-functioning, low-/intermediate-grade gastroenteropancreatic NENs on treatment with somatostatin analogues and radioligand therapy. Most of them had comorbidities. Only 8% of patients had high-grade NENs and 12% were receiving chemotherapy. Most patients had symptoms or signs of COVID-19, mainly fever and cough. Only 3 patients underwent sub-intensive treatment, whereas most of them received medical therapies, mostly antibiotics. In two third of cases, no changes occurred for the anti-NEN therapy. More than 80% of patients completely recovered without sequelae, whereas 7.8% patients died due to COVID-19. CONCLUSIONS: Patients included in this study reflect the typical NEN population regardless of SARS-CoV-2. In most cases, they overcome COVID-19 without need of intensive care, short-term sequelae and discontinuation of systemic oncological therapy.

COVID-19/therapy , Carcinoma, Neuroendocrine/therapy , Global Health , Adult , Aged , COVID-19/diagnosis , COVID-19/immunology , COVID-19/virology , Carcinoma, Neuroendocrine/diagnosis , Carcinoma, Neuroendocrine/immunology , Comorbidity , Female , Humans , Male , Middle Aged , Preliminary Data , Prospective Studies , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Young Adult
Eur J Cancer ; 144: 200-214, 2021 02.
Article in English | MEDLINE | ID: covidwho-987581


Neuroendocrine neoplasms (NENs) are a heterogeneous family of uncommon tumours with challenging diagnosis, clinical management and unique needs that almost always requires a multidisciplinary approach. In the absence of guidance from the scientific literature, along with the rapidly changing data available on the effect of COVID-19, we report how 12 high-volume NEN centres of expertise in 10 countries at different stages of the evolving COVID-19 global pandemic along with members of international neuroendocrine cancer patient societies have suggested to preserve high standards of care for patients with NENs. We review the multidisciplinary management of neuroendocrine neoplasms during the COVID-19 pandemic, and we suggest potential strategies to reduce risk and aid multidisciplinary treatment decision-making. By sharing our joint experiences, we aim to generate recommendations for proceeding to other institutions facing the same challenges.

COVID-19 , Carcinoid Tumor/therapy , Gastrointestinal Neoplasms/therapy , Medical Oncology/standards , Pancreatic Neoplasms/therapy , Thoracic Neoplasms/therapy , Carcinoid Tumor/diagnosis , Consensus , Gastrointestinal Neoplasms/diagnosis , Humans , Pancreatic Neoplasms/diagnosis , Thoracic Neoplasms/diagnosis